China SXT Pharmaceuticals, Inc. (SXTC) Company Bio
China Sxt Pharmaceuticals, Inc. engages in the development, manufacture, marketing, sales, research and development of Chinese traditional medicine. It sells Advanced TCMP, Fine TCMP and Regular TCMP products. The company sell its products under "Suxuantang" brand name. The company was founded by Zhou Feng in 2005 and is headquartered in Taizhou, China.
SXTC Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for SXTC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that China SXT Pharmaceuticals Inc ranked in the 9th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of China SXT Pharmaceuticals Inc, consider:
The company's debt burden, as measured by earnings divided by interest payments, is -2.1; that's higher than only 15.88% of US stocks in the Healthcare sector that have positive free cash flow.
The company's compound free cash flow growth rate over the past 1.87 years comes in at -0.24%; that's greater than merely 6.22% of US stocks we're applying DCF forecasting to.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of China SXT Pharmaceuticals Inc? See COO, EW, LUMO, TEVA, and NVST.
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that a fund granted to the Company for the key techniques incorporated into advanced Directly-Oral TCMPs derived from agriculture has been approved on February 19, 2020, by the Hailing District Science and Technology Bureau of Taizhou city.